TriSalus Life Sciences, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, 2026 | March 31, 2025 | |
| Cash flows from operating activities | ||
| Net income (loss) | $1,539 | $(10,375) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities | ||
| Depreciation | 135 | 172 |
| Non-cash lease expense | 31 | 173 |
| Change in fair value of SEPA, warrant and revenue base redemption liabilities | (3,900) | 835 |
| Change in fair value of contingent earnout liability | (7,402) | 820 |
| Paid-in-kind interest | — | 266 |
| Stock-based compensation expense | 2,472 | 1,620 |
| Allowance for credit losses | 52 | 39 |
| Loss on disposal of property and equipment | 1 | 117 |
| Amortization of debt issuance costs | 296 | 235 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 1,291 | (366) |
| Inventory, net | (701) | (114) |
| Prepaid expenses and other assets | (423) | 511 |
| Operating lease liabilities | (31) | (56) |
| Trade payables and accrued liabilities | 160 | 1,624 |
| Net cash used in operating activities | (6,480) | (4,499) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (141) | (754) |
| Proceeds from disposal of property and equipment | — | 40 |
| Net cash used in investing activities | (141) | (714) |
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock, net of issuance costs | 42,625 | — |
| Proceeds from the exercise of stock options for common stock | 32 | 279 |
| Debt issuance costs | (263) | (520) |
| Proceeds from the issuance of debt | — | 10,000 |
| Payments on finance lease liabilities | (9) | (71) |
| Net cash provided by financing activities | 42,385 | 9,688 |
| Increase in cash, cash equivalents and restricted cash | 35,764 | 4,475 |
| Cash, cash equivalents and restricted cash, beginning of period | 20,789 | 8,875 |
| Cash, cash equivalents and restricted cash, end of period | $56,553 | $13,350 |
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | 1,140 | 709 |
| Cash paid for income taxes | — | 1 |
| Supplemental disclosure of noncash items | ||
| Right-of-use assets obtained in exchange for new finance lease liabilities | 57 | — |
| Non-cash capital expenditures included in trade payables | 70 | 87 |
| Fixed assets purchased through exchange of finance lease right-of-use asset | — | 85 |
| Derecognition of finance lease right-of-use asset | — | (85) |
| Fair value of warrants issued with OrbiMed debt | — | 366 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.